Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2017-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators are performing a gene therapy clinical trial in Becker muscular dystrophy (BMD) and sporadic inclusion body myositis (sIBM) patients. Both of these conditions have an important common feature: loss of ability to walk because of weakness of the thigh muscles. The investigators plan to do a gene therapy trial to deliver a gene to muscle called follistatin (FS344) that can build muscle size and strength. If successful, the investigators can increase the size of the thigh muscle and potentially prolong a patient's ability to walk. The gene will be carried into the muscle by a virus called adeno-associated virus (AAV). This virus occurs naturally in muscle and does not cause any human disease, setting the stage for its safe use in a clinical trial.

Presently there is no treatment that can reverse Becker muscular dystrophy or sporadic inclusion body myositis. Only supportive care is currently possible.

In this study, subjects with either of these diseases will have shots of the follistatin gene injected directly into thigh muscle on one (first cohort) or both legs (2nd and 3rd cohort). One hundred and eighty days following the gene delivery, the muscle will undergo biopsy to look closely at the muscle to see if the muscle fibers are bigger. Between the time of the gene transfer and the muscle biopsy, patients will be carefully monitored for any side effects of the treatment. This will include an MRI of the thigh muscle before treatment and at day 180 following treatment. Blood and urine tests, as well as physical examination will be done on the subjects during the screening visit and on days 0, 1, 2, 7, 14, 30, 60, 90, and 180 to make sure that there are no side effects from the gene injections. Sutures will be removed 2 weeks post-biopsy.

Additional blood samples will be collected at 9, 12, 18, and 24 months. Patients will be seen at the end of 1st and 2nd years for a physical exam, assessment of muscle strength and appropriate blood tests.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy

NCT02354781

Duchenne Muscular Dystrophy

COMPLETED PHASE1/PHASE2

Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2

NCT02704325

Duchenne Muscular Dystrophy

WITHDRAWN PHASE1/PHASE2

Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy

NCT03333590

Duchenne Muscular Dystrophy

COMPLETED PHASE1/PHASE2

Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

NCT04433234

Duchenne Muscular Dystrophy

ACTIVE_NOT_RECRUITING PHASE2

A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.

NCT05689164

Duchenne Muscular Dystrophy

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Becker Muscular Dystrophy Sporadic Inclusion Body Myositis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Low Dose: 2E11 vg/kg of rAAV1.CMV.huFollistatin344 administered via intramuscular injection unilaterally to single quadriceps muscle (n=3, sIBM only)

Group Type EXPERIMENTAL

rAAV1.CMV.huFollistatin344

Intervention Type BIOLOGICAL

* First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)
* Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)
* Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)

Cohort 2

Mid Dose: 3E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)

Group Type EXPERIMENTAL

rAAV1.CMV.huFollistatin344

Intervention Type BIOLOGICAL

* First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)
* Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)
* Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)

Cohort 3

Low Dose: 6E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)

Group Type EXPERIMENTAL

rAAV1.CMV.huFollistatin344

Intervention Type BIOLOGICAL

* First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)
* Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)
* Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rAAV1.CMV.huFollistatin344

* First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)
* Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)
* Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All subjects \[sIBM and BMD must be ambulatory and have identifiable atrophy of the quadriceps muscle with muscle weakness ≥2 standard deviations below predicted using quantitative muscle testing (maximum voluntary isometric strength testing), and difficulty getting out of chairs, climbing stairs, and getting up from the floor.
* sIBM patients include males and post-menopause females of any ethnic or racial group. Diagnosis of sIBM is based on previously published criteria that include distribution of weakness (knee extensor weakness, finger flexor weakness) and histological presence of inflammation and vacuolar myopathy. Patients with inflammation, vacuolar changes and intracellular amyloid deposits or 15/18nm filaments fulfill criteria irrespective of clinical features.
* BMD patients include adult males (\>18yo) of any ethnic or racial group with proven mutation of dystrophin gene and continued ambulation after age 15 years old.
* Ability to cooperate for muscle testing
* Deficit in muscle strength greater than 2 standard deviation below age expectations
* Willingness of sexually active subjects with reproductive capacity (only male population) to practice reliable method of contraception until two negative sperm samples are obtained post gene transfer

Exclusion Criteria

* Active viral infection
* History or evidence of active infection with hepatitis C, hepatitis A or B, or HIV
* Patients with any other cause of muscle weakness based on medical history and screening physical exam including: myopathy (other dystrophies, polymyositis, and dermatomyositis), neuropathy (from any cause), myasthenia gravis, and weakness related to degenerative joint disease of the spine.
* Ongoing immunosuppressive therapy or immunosuppressive therapy within 3 months of starting the trial (e.g. corticosteroids, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, intravenous immunoglobulin, rituximab)
* Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer. Patients taking any of the following drugs will be excluded: drugs for treatment of myopathy or neuropathy or agents used to treat diabetes mellitus
* Knee or ankle contractures preventing proper muscle strength testing
* Patients with AAV1 neutralizing antibody titers ≥ 1:1600 as determined by ELISA immunoassay
* Patients with history of angina and patients with past history of myocardial infarction in the past 6 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No